Table 6.
Optimization and discontinuation of ustekinumab
| Author | N | Follow up time, week (mean or median) | Shortening of UST interval, n, (%) | Patients with discontinuation, n, (%) | Reason of discontinuation | Interval of UST in maintenance regimen before shortening | Interval of UST in maintenance regimen after shortening | Reason of interval shortening | Outcome after interval shortening |
| Fumery M et al7 | 103 | 48a | 65 (63.1) | 45 (43.7) | Lack of effectiveness (n = 41) Pregnancy (n = 1) Adverse event (n = 1) Personal decision after two episodes of mild skin rash (n=1) | Every 8 weeks | Every 4 weeks | NR | Clinical response (n=20) (30.7%) Clinical remission (n=17) (26.1%) |
| Chaparro M et al19 | 95 | 82b | 18 (27.2) | 34 (36.0) | Primary non-response (n=21) (22%) Loss of response in (n=12) (13%) Adverse event in (n=1) (1%) | Three patients (10%) started the maintenance phase with every-12-week schedule, 24 patients (80%) with every-8-week, and 3 (10%) with intensified schedule (every 6 weeks or every 4 weeks) | Every 4 or 6 weeks | Primary failure (n=10) (55%) Partial response (n=3) (17%) Loss of response (n=5) (28%) | 1 (5.6%) patient who escalated the dose due to loss of response reached remission. |
| Dalal RS et al20,24,25 | 108 | NR | 46 (42.6) | NR | NR | Every 8 weeks | Every 4 or 6 weeks | No initial response (n=22) (47.8%) Loss of response (n=20) (43.5%) | Remission (n=22) (55.0%) Response (n=27) (67.5%) Drug discontinuation or colectomy (n=12) (13%) within 16 weeks after intensification |
| Ochsenkühn T et al21 | 19 | NR | NR | 5 (26.3) | Refractory disease (n=4) (80%) Side effect (n=1) (20%) | Every 8 weeks | NR | NR | NR |
| Chiappetta MF et al22 | 67 | NR | 0 (0) | 9 (13.4) | Primary failure (n=1, 11.1%) Secondary failure (n=7, 77.8%) AEs (n=1, 11.1%) | Every 8 weeks | NR | NR | NR |
| Hong S et al23 | 19 | NR | NR | NR | NR | NR | NR | NR | NR |
| Haraikawa M et al26 | 19 | NR | NR | NR | NR | NR | NR | NR | NR |
| Yamana Y et al27 | 11 | NR | NR | NR | NR | NR | NR | NR | NR |
| Asaeda K et al28 | 20 | NR | NR | NR | NR | NR | NR | NR | NR |
| Ando K et al29 | 71 | NR | NR | NR | NR | NR | NR | NR | NR |
| Dominik E et al30 | 26 | NR | 14 (53.8) | 3 (11.5) | Lack of improvement (n=2) (66.7%) Colorectal cancer (n=1) (33.3%) | Every 8 weeks | Every 4 or 6 weeks | NR | NR |
a median
b mean
NR: not reported